Bionik Laboratories Corp (BNKL)

Etorro trading 970x250
Bionik Laboratories Corp (BNKL) Logo

About Bionik Laboratories Corp

Bionik Laboratories Corp., a robotics company, engages in designing, developing, and commercializing physical rehabilitation technologies, prosthetics, and assisted robotic products. It offers InMotion ARM that allows clinicians to deliver sensor motor therapy to the shoulder and elbow to develop new neural pathways; InMotion ARM/HAND for therapy involving reaching with grasp and release movements, and individual hand movements; and InMotion WRIST, a rehabilitation device that enables clinicians to deliver optimum intensive sensor motor wrist and forearm therapy to patients with neurological conditions. The company also engages in developing InMotion HOME, an upper extremity product that allows patients to extend their therapy for as long as needed while rehabilitating at home; ARKE, a robotic lower body exoskeleton designed for wheelchair bound individuals suffering from spinal cord injuries, strokes, and other mobility disabilities; and InMotion Connect, a solution to meet the data connectivity and analytics needs of hospitals and healthcare facilities. Bionik Laboratories Corp. was founded in 2010 and is headquartered in Toronto, Canada. Address: 483 Bay Street, Toronto, ON, Canada, M5G 2C9

Bionik Laboratories Corp News and around…

Latest news about Bionik Laboratories Corp (BNKL) common stock and company :

BIONIK Laboratories InMotion® Robotics Technology Meets the Recovery Demands from an Increase of Stroke Patients Brought on by Severe Cases of COVID-19
17 Dec, 2021 FinancialContent

BIONIK Laboratories Corp. (OTCQB: BNKL) (“BIONIK” or the “Company”), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced its unique position to meet the increased recovery demands from stroke patients who have suffered from a severe case of COVID-19.

BIONIK Laboratories to Participate at MEDICA, a Leading International Trade Show for the Medical Industry
11 Nov, 2021 FinancialContent

BIONIK Laboratories Corp. (OTCQB: BNKL) (“BIONIK” or the “Company”), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced its participation in the MEDICA Trade Show in Dusseldorf, Germany from November 15–18, 2021. MEDICA, the world forum for the medical industry, brings together leaders in medical technologies and equipment. BIONIK will have a booth located at 4H46 – Hall 4 – Physiotherapy and Orthopedics to showcase its InMotion® Robotic Therapy Systems.

BIONIK Laboratories Reports Second Quarter Fiscal Year 2022 Financial Results
10 Nov, 2021 FinancialContent

BIONIK Laboratories Corp. (OTCQB:BNKL), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today reported financial results for the second quarter of fiscal year 2022, ended September 30, 2021.

BIONIK Laboratories Announces Commercial Team Addition With Newly Hired Regional Sales Director, Tony Bellofatto
28 Oct, 2021 FinancialContent

BIONIK Laboratories Corp. (OTCQB: BNKL) ("BIONIK" or the "Company"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced the hiring of a new Regional Sales Director, Tony Bellofatto.

BIONIK Laboratories Reports a 72% Increase in Patient Sessions on its InMotion® Robotic Devices Since Launch of InMotion Connect™ Platform
22 Sep, 2021 FinancialContent

BIONIK Laboratories Corp. (OTCQB:BNKL) ("BIONIK" or the "Company"), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced hospitals and other healthcare facilities utilizing InMotion Connect™ have seen a 72% increase in patient sessions on InMotion® robotic devices nationwide since the launch of the proprietary data platform last year. Over that same period, the hospitals also experienced:

BIONIK Laboratories Reports Fiscal 2022 Q1 Financial Results
12 Aug, 2021 FinancialContent

BIONIK Laboratories Corp. (OTCQB:BNKL), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today reported financial results for its first quarter of fiscal year 2022, for the period ended June 30, 2021.

BIONIK Laboratories Announces $5 Million Capital Raise through Issuance of Convertible Notes
29 Jul, 2021 FinancialContent

BIONIK Laboratories Corp. (OTCQB:BNKL), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, announced today it has entered into a series of agreements to issue secured convertible promissory notes of the Company (the “Loan”) for a total of $5 million in gross proceeds to the Company.

BIONIK Laboratories Announces Resignation of CEO, Names Interim CEO
19 Jul, 2021 FinancialContent

BIONIK Laboratories Corp. (OTCQB:BNKL), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today has announced that Chief Executive Officer and Board Member Dr. Eric Dusseux has resigned as Chief Executive Officer and stepped down from the board, to pursue an opportunity outside the rehabilitation robotic device industry. The resignation is effective as of July 14, 2021. Rich Russo Jr., BIONIK’s current Chief Financial Officer, will assume the role of Interim CEO. The Board has begun a search for Dr. Dusseux’s successor.

BIONIK Laboratories Reports Fiscal 2021 Financial Results
24 Jun, 2021 FinancialContent

BIONIK Laboratories Corp. (OTCQB:BNKL), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today reported financial results for its fourth quarter and fiscal year 2021, for the periods ended March 31, 2021.

BIONIK Laboratories Reports Fiscal 2021 Q3 Financial Results
11 Feb, 2021 FinancialContent

BIONIK Laboratories Corp. (OTCQB:BNKL), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today reported financial results for its third quarter of fiscal year 2021, ended December 31, 2020.

BIONIK Laboratories Corp. Appoints Rich Russo, Jr. as CFO
30 Nov, 2020 FinancialContent

BIONIK Laboratories Corp. (OTCQB: BNKL), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced the appointment of Richard Russo, Jr. as Chief Financial Officer, effective today, November 30, 2020. Russo, Jr. will report directly to Dr. Eric Dusseux, BIONIK’s Chief Executive Officer.

BIONIK Laboratories Announces Fiscal 2021 Q2 Financial Results
12 Nov, 2020 FinancialContent

BIONIK Laboratories Corp. (OTCQB: BNKL), a robotics company focused on providing rehabilitation and assistive technology solutions to individuals with neurological and mobility challenges from hospital to home, today announced financial results for its second quarter of fiscal year 2021, ending September 30, 2020.

Bionik Laboratories Corp (BNKL) is a NASDAQ Common Stock listed in , ,

970x250